Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYMAKER-U01 Substudy 01H in previously treated nonsquamous NSCLC
2024-518761-10-00Phase 2Authorised
- Sponsor
- Merck & Co.
- Start
- Aug 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Raludotatug deruxtecan, Ifinatamab deruxtecan and Docetaxel control (3 arms). Primary endpoints: Objective response, Participants with at least one adverse event and 1 more. Planned start Aug 2025; status: authorised.
02
Drugs
raludotatug deruxtecanifinatamab deruxtecandocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-518761-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518761-10-00.